(MedPage Today) -- Almost 10 years ago, the FDA approved recombinant human bone morphogenetic protein-2, or BMP-2, a biologic agent that could grow bone where none existed -- and the product was a device-maker's dream, quickly generating hundreds of millions of dollars in sales.
But far away from the midwest headquarters of the device's maker, an orthopedic surgeon in Croatia began to have doubts about the miracle product.
